Children’s Healthcare of Atlanta Selected as an OUtMATCH Clinical Trial Site to Study Multiple Food Allergies

ATLANTA (January 10, 2020) – Children’s Healthcare of Atlanta, in collaboration with its research partner Emory University School of Medicine, was recently selected as an OUtMATCH clinical trial site to test whether omalizumab, a U.S. Food and Drug Administration (FDA)-approved treatment for asthma, could be effective at protecting patients with multiple food allergies.

There is currently no FDA-approved treatment to reduce food allergy risk, which affects an estimated 8% of children in the U.S. Anyone with an allergy must carefully avoid exposure, and those experiencing multiple food allergies are more likely to consume a food allergen accidentally, increasing their risk for a life-threatening adverse reaction.

“This study will be the largest trial to tackle the major unmet medical need associated with multiple food allergies, which affect 30 to 40 percent of food allergy patients,” said Brian Vickery, MD, Principal Investigator for OUtMATCH at Children’s and Associate Professor at Emory University.

Food allergies occur when the immune system reacts abnormally to certain foods, sometimes producing a severe response called anaphylaxis, which can be deadly. Often, rescue medications like epinephrine are used during a reaction, but there is no approved treatment to help stop reactions from occurring in the first place.

“Emergency department visits for food anaphylaxis nearly quadrupled in the U.S. from 2007 to 2016,” said Dr. Vickery, a Pediatric Allergist and Immunologist who also serves as Director of the Food Allergy Program at Children’s. “Almost 30,000 patients will experience a reaction requiring an emergency department visit each year.”

The five-year trial—Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Children and Adults (OUtMATCH)—is taking place at 10 sites nationwide and will test omalizumab injections in 225 children and adults ages 2 to 56, but most sites will primarily study children. Dr. Vickery and his team will enroll 20 to 25 participants up to age 21 with a peanut allergy and at least two other food allergies, including cow’s milk, egg white, wheat, cashew, hazelnut or walnut. They will test omalizumab alone and in combination with oral immunotherapy (OIT), a method for gradually introducing food that causes an allergic reaction. The final stage of the trial will focus on individualizing treatment regimens.

The research is sponsored by the National Institute of Allergy and Infectious Disease of the National Institutes of Health and will be administered through the Consortium of Food Allergy Research. Children’s was approved to begin enrolling patients on Oct. 30. To learn more, visit

For more information:

Julie Kuchta

Children's Healthcare of Atlanta


About Children’s Healthcare of Atlanta

As the only freestanding pediatric healthcare system in Georgia, Children’s Healthcare of Atlanta is the trusted leader in caring for kids. The not-for-profit organization’s mission is to make kids better today and healthier tomorrow through more than 60 pediatric specialties and programs, top healthcare professionals, and leading research and technology. Children’s is one of the largest pediatric clinical care providers in the country, managing more than one million patient visits annually at three hospitals, Marcus Autism Center, the Center for Advanced Pediatrics, urgent care centers and neighborhood locations. Consistently ranked among the top children’s hospitals by U.S. News & World Report, Children’s Healthcare of Atlanta has impacted the lives of kids in Georgia, across the United States and around the world for more than 100 years thanks to generous support from the community.

About Emory University School of Medicine

About Emory University School of Medicine
Emory University School of Medicine is a leading institution with the highest standards in education, biomedical research and patient care, with a commitment to recruiting and developing a diverse group of students and innovative leaders. Emory School of Medicine has more than 3,400 full- and part-time faculty, 592 medical students, 497 allied health students in five programs, 1,388 residents and fellows in 115 accredited programs, and 92 MD/PhD students. Medical school faculty received $588.4 million in external research funding in fiscal year 2022. The school is best known for its research and treatment in infectious disease, brain health, heart disease, cancer, transplantation, orthopaedics, pediatrics, renal disease, ophthalmology and geriatrics.

* Required fields